![]() | Fiscal NoteS.C.R. 5 2026 General Session Concurrent Resolution Directing PEHP Regarding Pain Medication by Weiler, Todd | ![]() |
| Ongoing | One-time | Total | |
|---|---|---|---|
| Net GF/ITF/USF (rev.-exp.) | $(338,400) | $0 | $(338,400) |
| Revenues | FY2026 | FY2027 | FY2028 |
| Total Revenues | $0 | $0 | $0 |
Enactment of this legislation likely will not materially impact state revenue.
| Expenditures | FY2026 | FY2027 | FY2028 |
| Transportation Fund | $0 | $50,900 | $50,900 |
| Other Financing Sources | $0 | $42,000 | $42,000 |
| Federal Funds | $0 | $111,800 | $111,800 |
| Dedicated Credits Revenue | $0 | $36,400 | $36,400 |
| General Fund | $0 | $313,900 | $313,900 |
| Income Tax Fund | $0 | $24,500 | $24,500 |
| Total Expenditures | $0 | $579,500 | $579,500 |
Enactment of this legislation could cost the Public Employees Health Program (PEHP) $579,500 ongoing beginning in FY 2027, with state agencies charged $313,900 from the General Fund, $24,500 from the Income Tax Fund, and $241,100 from other sources, for medication costs required by the legislation.
| FY2026 | FY2027 | FY2028 | |
| Net All Funds (rev-exp) | $0 | $(579,500) | $(579,500) |
Enactment of this legislation likely will not result in direct, measurable costs for local governments.
Enactment of this legislation likely will not result in direct expenditures from tax or fee changes for Utah residents and businesses.
Enactment of this legislation likely will not change the regulatory burden for Utah residents or businesses.
This bill does not create a new program or significantly expand an existing program.

